Contact Us and People


Sherif Hanafy Mahmoud, BSc(Pharm), MSc, PhD

Clinical Assistant Professor

Pharmacy and Pharmaceutical Sciences

About Me


Ph.D., Pharmacokinetics, University of Alberta (2010)

Master of Science, Clinical Pharmacy, Ain Shams University (2005)

Bachelor of Science, Pharmacy, Ain Shams University (2000)

Clinical Practice

Neurosciences Intensive Care Unit, University of Alberta Hospital, Edmonton, Alberta

Select Awards

Presidential Citation, Neurocritical Care Society, Boca Raton, FL, USA (2018)

Teaching Excellence Award, Faculty of Pharmacy, University of Alberta (2016)

Preceptor Recognition Award, Faculty of Pharmacy, University of Alberta (2016) 

Staff Pharmacist of The Year, University of Alberta Hospital Pharmacy, Alberta Health Services (2010)

Graduate Students Teaching Award, Faculty of Pharmacy, University of Alberta (2009)

Queen Elizabeth II Graduate Scholarship, University of Alberta (2009)

Pharmacy PhD Alumni Graduate students Scholarship, University of Alberta (2008)

Dr L Chatten Best Poster Award, Faculty of Pharmacy, University of Alberta (2007)


Areas of Interest: Neurocritical Care; Subarachnoid Hemorrhage; Antiepileptic Drugs; Clinical Pharmacokinetics; Epilepsy; Status Epilepticus

Overall research goal: 

My main research goal is to turn observations from benchside and bedside into clinical practice protocols that potentially will improve the outcome in patients with neurological emergencies (subarachnoid hemorrhage, intracerebral hemorrhage, ischemic stroke, traumatic brain injury and status epilepticus) and patients with epilepsy.

I. Subarachnoid Hemorrhage

Subarachnoid hemorrhage (SAH) is a neurological emergency characterized by the extravasation of blood into the subarachnoid space. Although SAH accounts for 5% of all strokes, given the relatively younger age at onset, it has a significant burden on productive-life years. The average mortality rate for SAH has been reported to range from 30-50%, with a significant proportion of survivors left with disability. Neurological and medical complications are common after SAH and contribute significantly to the overall prognosis. The goal of this research is pharmacotherapy optimization of existing therapies and translation of new therapeutics in SAH for the sake of preventing those complications and improving patient outcomes. 

II. Antiepileptic Drugs

       A. Pharmacotherapy optimization of antiepileptic drugs (AEDs) in seizures and epilepsy patients with superimposing comorbidities such as patients undergoing renal replacement therapies.

       B. Efficacy and safety of antiepileptic drugs in status epilepticus

       C. Therapeutic drug monitoring of antiepileptic drugs 

III. Altered pharmacokinetics and pharmacodynamics of drugs in critically ill

The goal of this research is to highlight altered pharmacokinetics and pharmacodynamics of drugs in critically ill and propose therapy optimization strategies to improve patients' outcome. Augmented renal clearance (ARC) is a manifestation of enhanced renal function seen in critically ill patients. It is currently defined as an increased creatinine clearance of greater than 130 ml/min/1.73 m2. ARC is a clinical phenomenon rapidly gaining recognition in the world of critical care. The use of regular unadjusted doses of renally eliminated drugs in patients with ARC might lead to therapy failure. 


PHARM 417: Neurology

PHARM 447: Psychiatry

PHARM 489: Seminars in Therapeutics and Professional Practice

PHARM 503: Advanced Pharmacotherapy

PHARM 523: Advanced Pharmacotherapy - Part I

PHARM 532: Patient Assessment

PHARM 533: Advanced Pharmacotherapy - Part II